Company Encyclopedia
View More
name
Yubo International Biotech Limited
YBGJ.US
Yubo International Biotech Limited, through its subsidiaries, focuses on the research, development, and application of endometrial stem cells. The company offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting services under the VIVCELL brand. Yubo International Biotech Limited is headquartered in Beijing, China.
1.935 T
YBGJ.USMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking340/401
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE46.21%A
    • Profit Margin6152688.89%A
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-100.07%E
    • Net Profit YoY44.71%B
    • Total Assets YoY-42.37%E
    • Net Assets YoY47.33%A
  • Cash ScoreD
    • Cash Flow Margin0.00%C
    • OCF YoY-100.07%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreE
    • Gearing Ratio268.07%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Yubo International Biotech Limited | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    YBGJ
    0.00%
    LB filings·
    US
    YBGJ
    0.00%

    Yubo International Biotech Limited | 10-Q: FY2025 Q2 Revenue: USD 0

    LB filings·
    US
    YBGJ
    0.00%
    LB filings·
    US
    YBGJ
    0.00%

    Yubo International Biotech Ltd. Announces Sale of 50.6 Million Shares in Private Placement to FlyDragon and ChinaOne

    Yubo International Biotech Ltd. has announced a private placement of 50.6 million shares of Class A Common Stock to FlyDragon International Limited and ChinaOne Technology Limited. The shares were sold at $0.05 each, with FlyDragon acquiring 42 million shares and ChinaOne receiving 8.6 million shares. This transaction included the cancellation of certain shareholder loans and was executed without registration under the Securities Act.

    Reuters·
    US
    YBGJ
    0.00%
    Reuters·
    US
    YBGJ
    0.00%

    Yubo International Biotech Limited | 10-Q: FY2025 Q1 EPS: USD 0

    LB filings·
    US
    YBGJ
    0.00%
    LB filings·
    US
    YBGJ
    0.00%

    Yubo International Biotech Ltd. Files Initial Beneficial Ownership Statement; Hu Nanping Listed as Director

    Yubo International Biotech Ltd. has filed an initial beneficial ownership statement, identifying Hu Nanping as the beneficial owner and Director. The full filing is accessible via EDGAR. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    YBGJ
    0.00%
    Reuters·
    US
    YBGJ
    0.00%
    © 2025 Longbridge｜Disclaimer